We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Analytical Cannabis Logo
Home > Resources > Industry Releases > Content Piece

Broughton Launches New Cannabinoids Service for Medicinal Cannabis & CBD Manufacturers

Published: Aug 23, 2022   
Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.

Broughton, a UK-based analytical testing and scientific consultancy organization, has launched a new cannabinoids service to help medicinal cannabis and CBD manufacturers achieve regulatory approval for their products in the UK and European Union (EU). The new service will also include CBD products and support with toxicology and stability studies for novel food applications.

The UK is the second-largest market for consumer CBD products, behind only the US. In fact, sales of CBD products reached £690m in 2021, doubling since 2019. Despite this, between January 2021 and April 2022, the Food Standards Agency rejected 680 of the 900 novel food applications for CBD it received. Another 42 were voluntarily withdrawn.

“One of the major barriers to getting regulatory approval of CBD products appears to be the toxicology and stability data that manufacturers must submit to regulators,” said Chris Allen, CEO of Broughton. “Manufacturers must provide clear evidence that their CBD products are safe to consume and illustrate that the quality of the product is not affected over time. Gathering this data requires experience in sensitive analytical testing and expert interpretation of test data. This is where our new service can help.”

“Broughton’s team of scientific experts perform highly sensitive analytical tests that assess chemical composition, toxicology, stability, and a variety of other requirements — in our Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) UKAS accredited testing laboratories. The service will cover medicinal cannabis and CBD products, including oils, tinctures, capsules, gummies, and food.

“The new cannabinoid service also includes regulatory consultancy to help manufacturers navigate UK and EU cannabis and CBD regulatory landscape. Our team has gained a wealth of experience working with UK, EU, and US regulators on next-generation nicotine products such as vapes and e-cigarettes. We are now bringing this analytical testing, scientific consultancy, and regulatory experience to the medicinal cannabis and CBD market. So, whether you’re just starting a new regulatory submission or need help with an ongoing application, we can help.

Broughton holds a UK Home Office controlled drugs license, and the company provides scientific and regulatory consultancy focused on the EU and UK medical cannabis and CBD markets. 

This article has been republished from materials provided by Broughton. Note: material may have been edited for length and content. For further information, please contact the cited source.


Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter